Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose HRT Combined With Alendronate in Postmenopausal Women With Low Bone Density
NCT00000430Phase 3Terminated
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- Start
- Oct 1999
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of alendronate, estrogen + progestin in osteoporosis, osteopenia, sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases. Started Oct 1999; status: terminated.
02
Drugs
alendronateestrogen + progestin
03
Conditions
osteoporosisosteopenia
Beyond the preview
Go deeper on NCT00000430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000430.